OBI Pharma Invited to Speak at World ADC Conference Innovative Linker Technology and GlycOBI® ADC Platform Capture Global Attention

OBI Pharma, Inc. (4174.TWO), with its independently developed Antibody-Drug Conjugate (ADC) technology platform, continues to gain global recognition. At the 15th World ADC San Diego conference, Dr. David Teng-Yi Huang, the Director and Head of Medicinal Chemistry at OBI Pharma, has been invited to deliver a presentation titled 'Exploring Novel ADC Platforms to Reimagine ADC from Concept to Clinical Success,' scheduled for 3:00 PM on November 6 (U.S. time).